semaglutide patent expiry 2031 Off-patent in 2026: the next revolution in anti-obesity medications Abel + Imray | Ozempic®

Adamidis PS, Pantazi D, Moschonas IC, Liberopoulos E, Tselepis AD

Studies consistently show that postmenopausal women who strength train maintain more muscle mass, have better bone density, and manage body composition more effectively than those who don't, regardless of what medications they're on

Alguna vez has luchado contra el cansancio frecuente, el metabolismo lento y la dificultad para controlar tu peso, incluso cuando tus hormonas estn dentro del rango normal

The article describes GLP-1 as a 30-amino-acid peptide that cannot easily cross the skin barrier without chemical modification or penetration enhancers, and says early-stage research puts peptide patch absorption below 5%, which it calls unsuitable for therapeutic dosing